Galapagos delivers novel osteoarthritis molecules in alliance with Servier
(Thomson Reuters ONE) -
Mechelen, Belgium; 23 July 2013 - Galapagos NV (Euronext: GLPG) announced today
the achievement of a late stage discovery milestone for small molecules against
a novel target in the osteoarthritis (OA) alliance with Servier. This milestone
triggered a payment to Galapagos of ?3 million and will contribute to Group
revenues in the first half of 2013.
"Galapagos already delivered multiple compounds against different OA targets
into late discovery and selected a preclinical candidate last year. Today's
achievement is consistent with our strategy to move multiple, novel mechanism-
of-action programs toward the clinic, thereby increasing the chances of success
in disease areas with high unmet medical needs," said Onno van de Stolpe, CEO of
Galapagos.
"Galapagos is delivering what we aimed for in our alliance to discover new oral
therapies in osteoarthritis. Servier is committed to developing medicines which
actually address the causes of osteoarthritis, a debilitating illness for which
no disease-modifying treatment is available," said Dr Patricia Belissa-Mathiot,
Director of Rheumatology Innovative Pole.
In July 2010, Servier and Galapagos announced their alliance to develop new oral
medicines for the treatment of osteoarthritis (OA). Galapagos is responsible
for the discovery and development of new candidate drugs against novel targets,
and Servier has an exclusive option to license these after the completion of
Phase 1 clinical trials. Galapagos is eligible to receive up to ?290 million in
success-based milestones, plus royalties on commercial sales. Galapagos also
retains exclusive US commercialization rights to all commercial compounds.
About Servier
Servier is a privately-run research based pharmaceutical company with a 2012
turnover of ?3.9 billion. Servier reinvests 25% of its turnover in Research &
Development in cardiovascular, metabolic, neurological, psychiatric and bone and
joint diseases as well as oncology. Servier is established in 140 countries
worldwide with over 20,000 employees. More info at: www.servier.com
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action,
with a large pipeline of five clinical, six pre-clinical, and 30 discovery
small-molecule and antibody programs in cystic fibrosis, inflammation,
antibiotics, metabolic disease, and other indications.
GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment
of rheumatoid arthritis and potentially other inflammatory diseases, currently
in Phase 2B studies in RA and about to enter Phase 2 studies in Crohn's
disease. AbbVie and Galapagos signed a worldwide license agreement whereby
AbbVie will be responsible for further development and commercialization after
Phase 2B. Galapagos has another selective JAK1 inhibitor in Phase 2 in lupus
and psoriasis, GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in
2012). GLPG0187 is a novel integrin receptor antagonist currently in a Phase
1B patient study in metastasis. GLPG0974 is the first inhibitor of FFA2 to be
evaluated clinically for the treatment of IBD; this program is currently in a
Proof of Concept Phase 2 study. GLPG1205 is a first-in-class molecule that
targets inflammatory disorders and is currently in a First-in-Human Phase 1
study.
The Galapagos Group, including fee-for-service companies BioFocus, Argenta and
Fidelta, has 800 employees and operates facilities in five countries, with
global headquarters in Mechelen, Belgium. Further information at: www.glpg.com
CONTACTS
Servier
Servier Communication Department
Tel: +33 1 55 72 60 37
presse(at)servier.fr
Galapagos NV
Onno van de Stolpe, Chief Executive Officer
Tel: +31 6 2909 8028
ir(at)glpg.com
Galapagos forward-looking statements
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such forward-
looking statements may involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition, performance
or achievements of Galapagos, or industry results, to be materially different
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance on
such forward-looking statements. These forward-looking statements speak only as
of the date of publication of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.
Galapagos delivers novel osteoarthritis molecules in alliance:
http://hugin.info/133350/R/1717970/571388.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE
[HUG#1717970]
Unternehmensinformation / Kurzprofil:
Datum: 23.07.2013 - 07:31 Uhr
Sprache: Deutsch
News-ID 280626
Anzahl Zeichen: 6276
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 237 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Galapagos delivers novel osteoarthritis molecules in alliance with Servier"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
